Jazz Pharmaceuticals plc (JAZZ)

Jazz Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	1,620	1,392	2,413	1,506	881.48	591.45
Short-Term Investments	580	1,050	580	120	-	-
Trading Asset Securities	-	-	0.96	3.78	-	-
Cash & Short-Term Investments	2,200	2,442	2,994	1,630	881.48	591.45
Cash Growth	31.73%	-18.44%	83.66%	84.93%	49.04%	-72.27%
Receivables	880.9	830.75	716.77	705.79	651.49	563.36
Inventory	443	416.96	480.45	597.04	714.06	1,073
Prepaid Expenses	200	152.48	177.41	185.48	91.91	131.41
Other Current Assets	244.5	323.95	260.58	317.03	267.19	252.39
Total Current Assets	3,968	4,166	4,629	3,435	2,606	2,611
Property, Plant & Equipment	264.1	258.74	227	234.99	301.38	343.42
Long-Term Investments	4.3	4.3	4.33	4.7	5.5	5
Goodwill	1,800	1,829	1,716	1,753	1,693	1,828
Other Intangible Assets	4,030	4,430	4,756	5,418	5,794	7,152
Long-Term Deferred Tax Assets	926.4	869.13	560.25	477.83	376.25	311.1
Long-Term Deferred Charges	6.6	7.55	9.49	6.48	9.25	12.03
Other Long-Term Assets	82	94.73	110.15	62.76	49.64	35.81
Total Assets	11,081	11,659	12,012	11,393	10,835	12,299

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	128.5	122.06	77.87	102.75	90.76	100.3
Accrued Expenses	968.5	974.51	821.98	748.21	757.86	588.41
Current Portion of Long-Term Debt	1,016	1,030	31	604.95	31	46.23
Current Portion of Leases	14.3	14.72	14.78	19.45	15.94	15.76
Current Income Taxes Payable	55.9	56.39	18.76	35.07	7.72	9.61
Current Unearned Revenue	-	-	-	-	0.46	2.09
Other Current Liabilities	47.2	44.95	74.19	26.26	29.46	46.9
Total Current Liabilities	2,231	2,243	1,039	1,537	933.19	809.3
Long-Term Debt	3,335	4,328	6,078	5,111	5,693	6,019
Long-Term Leases	43.6	54.33	43.5	64.26	77.05	93.47
Long-Term Unearned Revenue	-	-	-	-	-	0.46
Long-Term Deferred Tax Liabilities	528.9	594.47	676.74	847.71	944.34	1,301
Other Long-Term Liabilities	140.9	121.08	82.05	96.3	101.6	110.73
Total Liabilities	6,279	7,341	7,919	7,656	7,750	8,333

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	-	0.01	0.01	0.01	0.01	0.01
Additional Paid-In Capital	4,332	4,240	3,914	3,700	3,477	3,535
Retained Earnings	1,132	646.18	1,127	878.66	733.59	830.23
Comprehensive Income & Other	-661.9	-568.07	-947.14	-841.62	-1,125	-399.83
Shareholders' Equity	4,802	4,319	4,094	3,737	3,086	3,965
Total Liabilities & Equity	11,081	11,659	12,012	11,393	10,835	12,299

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	4,409	5,427	6,167	5,800	5,817	6,174
Net Cash (Debt)	-2,210	-2,985	-3,173	-4,170	-4,936	-5,583
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-34.35	-48.96	-48.07	-57.86	-78.92	-93.53
Filing Date Shares Outstanding	64.91	61.56	60.73	62.35	63.33	61.74
Total Common Shares Outstanding	64.8	61.44	60.63	62.26	63.21	61.63
Working Capital	1,737	1,924	3,590	1,899	1,673	1,802
Book Value Per Share	74.10	70.30	67.52	60.03	48.82	64.34
Tangible Book Value	-1,028	-1,940	-2,378	-3,434	-4,401	-5,015
Tangible Book Value Per Share	-15.86	-31.58	-39.22	-55.16	-69.63	-81.36
Land	71.8	72.23	71.9	70.91	68.94	64.01
Machinery	130.5	129.33	116.14	107.57	100.49	99.73
Construction In Progress	70.5	49.64	34.49	18.66	67.39	86.51
Leasehold Improvements	65.6	63.57	70.2	67.72	64.78	66.32

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: May 5, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 28, 2026

Data Sources Report a data error